Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Sarcoma 2Head & Neck 2Gynecologic 2Breast 2Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Riluzole × Dermatologic × 1 year × Clear all
NCT01303341 2026-04-13

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡